ARS Pharmaceuticals, Inc. (SPRY)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Needle-free Intranasal	30.00K	Log In
Needle-free Intranasal Growth	-97.72%	Log In

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	30.00K	Log In
United States Growth	-97.72%	Log In